In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1728-1733

  Reyes, Noe ^a   Aggen, James B ^a   Kostrub, Corwin F ^a  

^a Achaogen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACHN 490; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPTICEMIA; SERRATIA INFECTION; SERRATIA MARCESCENS; SURVIVAL;

AMINOGLYCOSIDES; ANIMALS; ESCHERICHIA COLI; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; SEPSIS; THIGH;

EID: 79953195147     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00862-10     Document Type: Article

References (31)

1. Aggen, J. B., et al. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54:4636-4642.
2. Alvarez-Lerma, F. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 22:387-394.
3. Black, J., B. Calesnick, D. Williams, and M. J. Weinstein. 1963. Pharmacology of gentamicin, a new broad-spectrum antibiotic, p. 138-147. Antimicrob. Agents Chemother. 1962.
4. Bratu, S., et al. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Craig, W. 1993. Relevance of animal models for clinical treatment. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):S55-S57.
7. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
8. Doi, Y., and Y. Arakawa. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45:88-94.
9. Dupont, H., H. Mentec, J. P. Sollet, and G. Bleichner. 2001. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 27:355-362. (Pubitemid 32249978)
10. Frimodt-Moller, N., J. Knudsen, and F. Espersen. 1999. The mouse peritonitis/sepsis model, p. 127-136. In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, New York, NY.
11. Gudmundsson, S., et al. 1993. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J. Antimicrob. Chemother. 31(Suppl. D):177-191.
12. Gudmundsson, S., and H. Erlendsdottir. 1999. Murine thigh infection model, p. 137-144. In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, Inc., New York, NY.
13. Infectious Diseases Society of America. 2010. The 10x'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50:1081-1083.
14. Institute of Laboratory Animal Research, Commission on Life Sciences, and National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
15. Jana, S., and J. K. Deb. 2006. Molecular understanding of aminoglycoside action and resistance. Appl. Microbiol. Biotechnol. 70:140-150.
16. Jao, R. L., and G. G. Jackson. 1964. Gentamicin sulfate, new antibiotic against Gram-negative bacilli. Laboratory, pharmacological, and clinical evaluation. JAMA 189:817-822.
17. Kollef, K. E., et al. 2008. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281-287.
18. Kollef, M. H. 2000. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31(Suppl. 4):S131-S138.
19. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1990. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thighinfection and pneumonitis models. Scand. J. Infect. Dis. Suppl. 74:179-184.
20. Leggett, J. E., et al. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
21. Mueller, E. W., et al. 2005. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J. Trauma 58:94-101.
22. Oplustil, C. P., R. Nunes, and C. Mendes. 2001. Multicenter evaluation of resistance patterns of Klebsiella pneumoniae, Escherichia coli, Salmonella spp and Shigella spp isolated from clinical specimens in Brazil: RESISTNET Surveillance Program. Braz. J. Infect. Dis. 5:8-12.
23. Patel, G., S. Huprikar, S. H. Factor, S. G. Jenkins, and D. P. Calfee. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29:1099-1106.
24. Rhomberg, P. R., and R. N. Jones. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn. Microbiol. Infect. Dis. 65:414-426.
25. Schatz, A., E. Bugie, and S. A. Waksman. 2005. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Clin. Orthop. Relat. Res. 437:3-6.
26. Schwaber, M. J., and Y. Carmeli. 2008. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911-2913.
27. Shin, J. H., et al. 2008. High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. Microb. Drug Resist. 14:221-226.
28. Spink, W. W., W. H. Hall, and V. Ferris. 1945. Clinical significance of staphylococci with natural or acquired resistance to the sulfonamides and to penicillin. JAMA 128:555-559.
29. Tsakris, A., J. Douboyas, and L. S. Tzouvelekis. 1997. High rates of resistance to piperacillin/tazobactam among Escherichia coli and Klebsiella pneumoniae strains isolated in a Greek hospital. Diagn. Microbiol. Infect. Dis. 29:39-41.
30. Urban, C., et al. 2008. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin. Infect. Dis. 46:e127-e130.
31. Vogelman, B., et al. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.